```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 2922 Introduced in Senate (IS)]

<DOC>

118th CONGRESS
  1st Session
                                S. 2922

            To advance population research for chronic pain.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

           September 26 (legislative day, September 22), 2023

  Mr. Casey (for himself, Mrs. Blackburn, Mr. Kaine, and Mr. Cramer) 
introduced the following bill; which was read twice and referred to the 
          Committee on Health, Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL

 
            To advance population research for chronic pain.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Advancing Research for Chronic Pain 
Act of 2023''.

SEC. 2. NATIONAL CHRONIC PAIN INFORMATION SYSTEM.

    Part P of title III of the Public Health Service Act (42 U.S.C. 
280g et seq.) is amended by adding at the end the following:

``SEC. 399V-8. CHRONIC PAIN RESEARCH.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention in consultation with the 
Director of the National Center for Injury Prevention and Control and 
the Director of the National Center for Chronic Disease Prevention and 
Health Promotion, and in coordination with the NIH Helping to End 
Addiction Long-term Initiative and with other agencies as the Secretary 
determines appropriate, shall--
            ``(1) utilize available Federal research data to clarify 
        the incidence and prevalence of chronic pain from any source, 
        including injuries, operations, and diseases and conditions;
            ``(2) identify gaps in the available research data and 
        collect deidentified population research data using medical 
        claims and survey data to fill gaps in available research data, 
        such as information concerning--
                    ``(A) incidence and prevalence of specific pain 
                conditions;
                    ``(B) demographics and other information, such as 
                age, race, ethnicity, gender, and geographic location;
                    ``(C) the incidence and prevalence of known chronic 
                pain conditions, as well as of diseases and conditions 
                that include or lead to pain;
                    ``(D) risk factors that may be associated with 
                chronic pain conditions, such as genetic and 
                environmental risk factors and other information, as 
                appropriate;
                    ``(E) diagnosis and progression markers;
                    ``(F) both direct and indirect costs of illness;
                    ``(G) the epidemiology of the conditions;
                    ``(H) the detection, management, and treatment of 
                the conditions;
                    ``(I) the epidemiology, detection, management, and 
                treatment of frequent secondary or co-occurring 
                conditions, such as depressive, anxiety, and substance 
                use disorders;
                    ``(J) the utilization of medical and social 
                services by patients with chronic pain conditions, 
                including the direct health care costs of pain 
                treatment, both traditional and alternative, and the 
                indirect costs (such as missed work, public and private 
                disability, and reduction in productivity); and
                    ``(K) the effectiveness of evidence-based treatment 
                approaches on chronic pain conditions;
            ``(3) develop, in collaboration with individuals and 
        organizations with appropriate chronic pain expertise, 
        including patients or patient advocates, epidemiologists, 
        representatives of national voluntary health associations, 
        health information technology experts, clinicians, and research 
        scientists, standard definitions and approaches for population 
        research on chronic pain to efficiently promote greater 
        comparability of data; and
            ``(4) disseminate, pursuant to the public webpage under 
        subsection (b), and, as appropriate, to the public and to other 
        Federal departments and agencies, any findings, developed 
        population research standards, and available Federal data 
        sources related to chronic pain.
    ``(b) Dissemination.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, shall establish a 
public webpage, to be known as the Chronic Pain Information Hub, that--
            ``(1) aggregates and summarizes available Federal data 
        sources, indicators, and peer-reviewed research related to 
        chronic pain;
            ``(2) includes an up-to-date summary of complete, underway, 
        and planned data collection and analysis related to chronic 
        pain that is conducted and supported by the Centers for Disease 
        Control and Prevention; and
            ``(3) translates research findings into clinical tools and 
        resources, recommendations for closing research gaps, and 
        recommendations for population research standards for 
        researchers, with recommendations updated annually to 
        incorporate research findings from the prior year.
    ``(c) Conflicts of Interest.--If an individual or organization that 
collaborates with the Secretary in carrying out subsection (a) receives 
a payment or other transfer of value of a type described in section 
1128G(a)(1)(A)(vi) of the Social Security Act from a manufacturer of a 
drug (including a biological product) or device that would be required 
to be disclosed pursuant to section 1128G(a)(1) of the Social Security 
Act, if the individual or organization were a covered recipient or if 
such disclosure were required upon request of or by designation on 
behalf of a covered recipient pursuant to such section, the individual 
or organization shall disclose to the Secretary information regarding 
such payment or other transfer of value. The Secretary shall make such 
disclosures publicly available.
    ``(d) Report.--Not later than 2 years after the date of the 
enactment of the Advancing Research for Chronic Pain Act of 2023, the 
Secretary shall submit a report to Congress concerning the 
implementation of this section. Such report shall include information 
on--
            ``(1) the development and maintenance of the Chronic Pain 
        Information Hub;
            ``(2) the information made available through the Chronic 
        Pain Information Hub;
            ``(3) the data gaps identified, and planned efforts to 
        address such gaps;
            ``(4) the process established for soliciting feedback from 
        collaborators; and
            ``(5) feedback received from collaborators.
    ``(e) Definition.--In this section, the term `chronic pain' means 
persistent or recurrent pain lasting longer than 3 months.
    ``(f) Authorization of Appropriations.--To carry out this section, 
there is authorized to be appropriated such sums as may be necessary 
for each of fiscal years 2024 through 2028.''.
                                 <all>
```